S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:ENDP

Endo International (ENDP) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.0090
$0.01
50-Day Range
$0.28
$0.75
52-Week Range
$0.28
$7.07
Volume
75,712 shs
Average Volume
28.19 million shs
Market Capitalization
$2.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Endo International MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.62
Upright™ Environmental Score
News Sentiment
0.01mentions of Endo International in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-83.33%
From $0.78 to $0.13 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.95 out of 5 stars


ENDP stock logo

About Endo International (NASDAQ:ENDP) Stock

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.


ENDP Stock News Headlines

This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
The World's First "$20 Trillion Drug
?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>
See More Headlines
Receive ENDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endo International and its competitors with MarketBeat's FREE daily newsletter.

ENDP Company Calendar

Last Earnings
11/04/2021
Today
9/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:ENDP
CUSIP
29264F20
Employees
3,103
Year Founded
1997

Profitability

Net Income
$-613,240,000.00
Pretax Margin
-91.14%

Debt

Sales & Book Value

Annual Sales
$2.99 billion
Cash Flow
$0.17 per share
Book Value
($13.60) per share

Miscellaneous

Free Float
232,321,000
Market Cap
$2.35 million
Optionable
Optionable
Beta
1.15

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Blaise A. Coleman (Age 48)
    Pres, CEO & Director
    Comp: $20.93M
  • Mr. Mark T. Bradley (Age 52)
    Exec. VP & CFO
    Comp: $6.27M
  • Mr. Matthew Joseph Maletta (Age 50)
    Exec. VP, Chief Legal Officer & Company Sec.
    Comp: $7.02M
  • Mr. Patrick A. Barry (Age 54)
    Exec. VP & Pres of Global Commercial Operations
    Comp: $6.15M
  • Frank B. Raciti
    VP, Controller & Chief Accounting Officer
  • Ms. Cheryl Stouch
    Sr. VP of Information Technology & Chief Information Officer
  • Ms. Laure E. Park
    Sr. VP of Investor Relations & Corp. Affairs
  • Ms. Susan Williamson
    Sr. VP & Chief Compliance Officer
  • Ms. Tracy Basso
    Chief HR Officer
  • Mr. James Papp
    Head of Endo Ventures Limited & Sr. VP of Global Supply Chain













ENDP Stock - Frequently Asked Questions

How were Endo International's earnings last quarter?

Endo International plc (NASDAQ:ENDP) announced its earnings results on Thursday, November, 4th. The company reported $0.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.46 by $0.34. The firm had revenue of $772.03 million for the quarter, compared to analyst estimates of $667.94 million. Endo International had a negative trailing twelve-month return on equity of 34.25% and a negative net margin of 93.31%. The business's revenue was up 21.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.52 EPS.

What is Paul Campanelli's approval rating as Endo International's CEO?

25 employees have rated Endo International Chief Executive Officer Paul Campanelli on Glassdoor.com. Paul Campanelli has an approval rating of 86% among the company's employees.

What other stocks do shareholders of Endo International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Endo International investors own include Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Mallinckrodt (MNK), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Micron Technology (MU), Cleveland-Cliffs (CLF), Pfizer (PFE), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

What is Endo International's stock price today?

One share of ENDP stock can currently be purchased for approximately $0.01.

How much money does Endo International make?

Endo International (NASDAQ:ENDP) has a market capitalization of $2.35 million and generates $2.99 billion in revenue each year. The company earns $-613,240,000.00 in net income (profit) each year or ($11.07) on an earnings per share basis.

How many employees does Endo International have?

The company employs 3,103 workers across the globe.

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The official website for the company is www.endo.com. The company can be reached via phone at (531) 268-2000, via email at relations.investor@endo.com, or via fax at 800-329-3636.

This page (NASDAQ:ENDP) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -